MX344385B - Sal de amina y cristales de la misma. - Google Patents
Sal de amina y cristales de la misma.Info
- Publication number
- MX344385B MX344385B MX2015002209A MX2015002209A MX344385B MX 344385 B MX344385 B MX 344385B MX 2015002209 A MX2015002209 A MX 2015002209A MX 2015002209 A MX2015002209 A MX 2015002209A MX 344385 B MX344385 B MX 344385B
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- ease
- pharmaceutical
- term storage
- drug
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- -1 Amine salt Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 230000007774 longterm Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- FXVDFPWMKDFSDI-OKDDVETASA-N 2-[2-[(1r,5r)-2-oxo-5-[(1e,4s)-7,8,8-trifluoro-4-hydroxy-4-methylocta-1,7-dienyl]cyclopentyl]ethylsulfanyl]-1,3-thiazole-4-carboxylic acid Chemical class FC(F)=C(F)CC[C@@](O)(C)C\C=C\[C@H]1CCC(=O)[C@@H]1CCSC1=NC(C(O)=O)=CS1 FXVDFPWMKDFSDI-OKDDVETASA-N 0.000 abstract 1
- 208000004168 Underactive Urinary Bladder Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Hydrogenated Pyridines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Se proporciona un compuesto que puede servir como un fármaco para el tratamiento de la vejiga subactiva, que puede ser administrado oralmente y posee poco riesgo de efectos colaterales. Se proporcionan también los cristales que son ventajosos como un fármaco a granel de un producto farmacéutico en términos de estabilidad, almacenamiento a largo plazo, facilidad de manejo, facilidad de formulación, y similares, las sales del ácido 2-[(2-{1R,5R)-2-oxo-5-[(1E,4S)-7,8,8-trifluoro-4-hidroxi-4-metil- 1,7-octadien-1-il]ciclopentil}etil)tio]-1,3-tiazol-4-carboxílico, o una mezcla de diastereoisómeros del mimo, y 4-piperidinmetanol son cristales extremadamente químicamente estables y por lo tanto permite el almacenamiento a largo plazo y son muy útiles como el fármaco a granel de una composición farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012191080 | 2012-08-31 | ||
| PCT/JP2013/073442 WO2014034902A1 (ja) | 2012-08-31 | 2013-08-30 | アミン塩とその結晶 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015002209A MX2015002209A (es) | 2015-05-08 |
| MX344385B true MX344385B (es) | 2016-12-14 |
Family
ID=50183705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015002209A MX344385B (es) | 2012-08-31 | 2013-08-30 | Sal de amina y cristales de la misma. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9643940B2 (es) |
| EP (1) | EP2891651B1 (es) |
| JP (1) | JP6131956B2 (es) |
| KR (1) | KR102119619B1 (es) |
| CN (1) | CN104603117B (es) |
| AU (1) | AU2013309872B2 (es) |
| BR (1) | BR112015004459B1 (es) |
| CA (1) | CA2882732C (es) |
| DK (1) | DK2891651T3 (es) |
| ES (1) | ES2623788T3 (es) |
| HK (1) | HK1210168A1 (es) |
| HU (1) | HUE032816T2 (es) |
| IL (1) | IL237432B (es) |
| MX (1) | MX344385B (es) |
| MY (1) | MY177737A (es) |
| NZ (1) | NZ705340A (es) |
| PH (1) | PH12015500389A1 (es) |
| PL (1) | PL2891651T3 (es) |
| PT (1) | PT2891651T (es) |
| RU (1) | RU2658823C2 (es) |
| SG (1) | SG11201501451SA (es) |
| TW (1) | TWI597274B (es) |
| WO (1) | WO2014034902A1 (es) |
| ZA (1) | ZA201501374B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022543401A (ja) * | 2019-08-04 | 2022-10-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | フルエンスルホンの製造方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (es) | 1970-06-10 | 1975-02-04 | ||
| JPS5231404B1 (es) | 1971-04-28 | 1977-08-15 | ||
| FR2204408A1 (en) * | 1972-10-27 | 1974-05-24 | Wirth Pierre | Phenylbutazone salts - sol in water and well tolerated |
| JPS57156460A (en) | 1981-03-20 | 1982-09-27 | Ono Pharmaceut Co Ltd | Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation |
| JPS60197667A (ja) | 1984-03-19 | 1985-10-07 | Ono Pharmaceut Co Ltd | ６―ケト―プロスタグランジン類似化合物及びその製造方法 |
| DK1008588T3 (da) | 1997-02-10 | 2003-07-28 | Ono Pharmaceutical Co | 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel |
| JPH11130678A (ja) | 1997-08-27 | 1999-05-18 | Kaken Pharmaceut Co Ltd | 神経圧迫による神経障害改善剤 |
| IL159996A0 (en) | 2001-07-23 | 2004-06-20 | Ono Pharmaceutical Co | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| WO2003074483A1 (fr) | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
| WO2004008411A1 (en) | 2002-07-11 | 2004-01-22 | Nokia Corporation | Method and device for automatically changing a digital content on a mobile device according to sensor data |
| WO2004065365A1 (ja) | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| US20070167403A1 (en) | 2003-04-03 | 2007-07-19 | Yoshifumi Takenobu | Remedy for spinal canal stenosis |
| EP1707208A4 (en) | 2003-12-05 | 2010-03-17 | Ono Pharmaceutical Co | PROMOTER OF BLOOD FLOW IN THE TISSUES OF THE HORSE TAIL |
| WO2005061492A1 (ja) | 2003-12-22 | 2005-07-07 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびそれらを有効成分とする薬剤 |
| JP4888775B2 (ja) | 2004-08-10 | 2012-02-29 | 小野薬品工業株式会社 | Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤 |
| JP4893999B2 (ja) | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
| TWI404529B (zh) * | 2005-06-03 | 2013-08-11 | Ono Pharmaceutical Co | 神經再生及／或保護劑 |
| JP5630264B2 (ja) | 2008-06-06 | 2014-11-26 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩剤 |
| CN102803239B (zh) * | 2009-06-10 | 2015-04-15 | 小野药品工业株式会社 | 具有膀胱排尿肌收缩活性和尿道括约肌舒张活性的化合物 |
-
2013
- 2013-08-30 BR BR112015004459-0A patent/BR112015004459B1/pt not_active IP Right Cessation
- 2013-08-30 JP JP2014533137A patent/JP6131956B2/ja active Active
- 2013-08-30 CA CA2882732A patent/CA2882732C/en not_active Expired - Fee Related
- 2013-08-30 EP EP13832178.1A patent/EP2891651B1/en active Active
- 2013-08-30 MX MX2015002209A patent/MX344385B/es active IP Right Grant
- 2013-08-30 DK DK13832178.1T patent/DK2891651T3/en active
- 2013-08-30 PT PT138321781T patent/PT2891651T/pt unknown
- 2013-08-30 MY MYPI2015700583A patent/MY177737A/en unknown
- 2013-08-30 TW TW102131218A patent/TWI597274B/zh not_active IP Right Cessation
- 2013-08-30 SG SG11201501451SA patent/SG11201501451SA/en unknown
- 2013-08-30 WO PCT/JP2013/073442 patent/WO2014034902A1/ja active Application Filing
- 2013-08-30 AU AU2013309872A patent/AU2013309872B2/en not_active Ceased
- 2013-08-30 KR KR1020157004896A patent/KR102119619B1/ko active IP Right Grant
- 2013-08-30 ES ES13832178.1T patent/ES2623788T3/es active Active
- 2013-08-30 RU RU2015111568A patent/RU2658823C2/ru active
- 2013-08-30 CN CN201380045485.XA patent/CN104603117B/zh not_active Expired - Fee Related
- 2013-08-30 US US14/424,215 patent/US9643940B2/en active Active
- 2013-08-30 PL PL13832178T patent/PL2891651T3/pl unknown
- 2013-08-30 HU HUE13832178A patent/HUE032816T2/en unknown
- 2013-08-30 NZ NZ705340A patent/NZ705340A/en not_active IP Right Cessation
-
2015
- 2015-02-23 PH PH12015500389A patent/PH12015500389A1/en unknown
- 2015-02-26 IL IL237432A patent/IL237432B/en active IP Right Grant
- 2015-02-27 ZA ZA2015/01374A patent/ZA201501374B/en unknown
- 2015-11-09 HK HK15111010.6A patent/HK1210168A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4490C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| BR112018008880A8 (pt) | composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7 | |
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| TN2012000544A1 (en) | Soluble guanylate cyclase activators | |
| ECSP13012569A (es) | Formulación de premezcla de dexmedetomidina | |
| NZ631100A (en) | Soft chewable pharmaceutical products | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| WO2010089768A3 (en) | Bortezumib containing pharmaceutical composition | |
| NZ741318A (en) | Compound for treating or preventing hyperuricemia or gout | |
| HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
| SA515360956B1 (ar) | مشتق من 2-أسيل امينو ثيازول أو ملح من أملاحه | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| WO2012002644A3 (en) | Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability | |
| WO2012161518A3 (ko) | ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물 | |
| TR201908676T4 (tr) | Mesane idrar yolu hastalıklarının önlenmesinde veya tedavisinde kullanıma yönelik 2-asilaminotiyazol türevi. | |
| PH12017502252B1 (en) | Stable pharmaceutical composition for oral administration | |
| PH12015500389A1 (en) | Amine salt and crystals thereof | |
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| BR112012020223A2 (pt) | "pélete farmacêutica de fator de crescimento epidérmico administrável por via oral" | |
| WO2011095801A3 (en) | Liquid pharmaceutical composition for buccal administration comprising morphine | |
| PH12016500563A1 (en) | 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |